A class-action lawsuit in California accuses wearable device manufacturer Oura of misrepresenting the accuracy of its sleep tracking for years. Specifically, the lawsuit challenges the claim that the Oura Ring can detect sleep stages with up to 95 percent accuracy. According to the complaint, the actual accuracy rate in a scientific study is just 53 percent—barely better than flipping a coin.
Key points at a glance:
- On August 20, 2026, the Clarkson Law Firm filed a lawsuit against Oura Inc. and Oura Health Oy on behalf of the plaintiff, Madison Surber (Case 3:26-cv-08686, U.S. District Court, Northern District of California).
- The complaint challenges advertising claims such as “95% Sleep Staging Accuracy” and “Built for accuracy.”
- As evidence, the complaint cites a March 2025 study published in *Nature* that measured only 53.18 percent accuracy in sleep stage detection.
- Oura rejects the allegations and points to its own validation studies.
- The plaintiffs are seeking damages, a ban on advertising the disputed claims, and class-action status.
What the lawsuit specifically alleges against Oura
At the heart of the lawsuit is a simple technical objection: A ring on the finger cannot directly measure the signals that sleep labs use to determine sleep stages. Clinical polysomnography uses EEG, EOG, EMG, and ECG sensors that record brain activity, eye movements, muscle tension, and heart electrical activity. According to the complaint, the Oura Ring does not record any of these. Instead, it derives sleep stages from heart rate, skin temperature, and movement, and estimates the rest using an algorithm.
It is precisely this estimation that is the problem, according to the plaintiffs: Oura is selling a calculation as a measurement. The rings were advertised, among other things, as an “alternative to PSG sleep studies,” meaning a substitute for a sleep lab. Anyone who uses such values to make informed decisions about health issues like sleep apnea or chronic sleep deprivation is basing those decisions on data that is significantly less reliable than stated.
From 95 Percent to a 50-50 Chance: A Comparison of the Numbers
Oura itself has adjusted its accuracy claims several times over the years, consistently revising them upward. The complaint contrasts these advertising claims with the results of independent studies:
| Source | Stated or measured accuracy |
|---|---|
| Oura advertising (current) | 95% sleep stage accuracy compared to a sleep lab |
| Oura advertising (previous) | 79% agreement with polysomnography |
| Nature study (March 2025) | 53.18% accuracy in sleep stage classification |
| Sleep Advances (2026) | Significantly lower accuracy in older adults |
| Oura’s own validation study (2024) | Significant error rate when sleep cycle lengths vary |
The 53 percent accuracy rate from the Nature study is problematic because it is barely above the level that a random assignment of sleep stages would achieve. The lawsuit highlights this by stating that the accuracy rate corresponds to “a coin flip’s chance of being correct.”
Oura’s Response
Oura responded to the lawsuit on August 22, 2026, and rejected the allegations. The company argues that peripheral physiological signals such as heart rate, skin temperature, and movement can indeed be used reliably to classify sleep stages, even without direct measurement of brain waves. As evidence, Oura cites four of its own validation studies from 2018 to 2024, which were tested against polysomnography.
What is striking is what is missing from Oura’s statement: the company does not address the *Nature* study with the 53 percent result. Whether this will change remains to be seen as the proceedings unfold; a court date has not yet been set.
Not an Isolated Case: Wearables and Their Accuracy Claims
The case strikes a chord that extends beyond Oura. The market for smart rings is growing rapidly, from Samsung’s Galaxy Ring 2 to Ultrahuman’s Emerald to Garmin’s first forays into this form factor. Almost every manufacturer now advertises health and sleep analytics that go far beyond simple activity tracking.
The real problem is rarely the technology itself, but rather the way it is advertised. A ring that tracks trends in sleep patterns over weeks can still be useful for many users, even if individual nightly measurements aren’t clinically accurate. But when the same technology is marketed as a direct alternative to a sleep lab, it creates expectations that the sensors simply cannot meet.
What This Means for Oura Ring Owners
For current users, the lawsuit does not initially change anything about the device itself. Anyone who uses their Oura Ring to get a general idea of sleep duration, recovery, and trends can continue to do so. However, for specific health concerns—such as a suspected sleep disorder—the ring is no substitute for a medical diagnosis or a sleep lab, regardless of how the lawsuit turns out.
Should the class-action lawsuit succeed, affected buyers in the U.S. may be entitled to compensation. For the German market, a U.S. lawsuit has no direct legal effect for the time being, but it is likely to fuel the debate here as well regarding accuracy claims for health wearables, similar to how class-action lawsuits against streaming providers have recently done in response to price increases.
Conclusion
The class-action lawsuit against Oura highlights a fundamental problem in the wearable industry: marketing figures and study results often diverge more widely than advertising would suggest. It remains to be seen whether the allegations will be confirmed in court. For buyers, it’s already worth taking a skeptical look at any accuracy claims a manufacturer puts forward without citing an independent source.
Sources: TechCrunch,
